There are currently 651 clinical trials in Charleston, South Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical University of South Carolina, GSK Investigational Site, Hollings Cancer Center at Medical University of South Carolina and Medical University of South Carolina (MUSC). Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
NCT02235857
Recruiting
Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma cholesterol level. The system was originally developed for the treatment of patients with serious dyslipidemia such as familial hypercholesterolemia and then applied to improve the dyslipidemia, a common complication of nephrotic syndrome and found to bring about improvement not only with the dyslipid... Read More
Gender:
All
Ages:
21 years and below
Trial Updated:
03/07/2023
Locations: Medical University of South Carolina Children's Hospital, Charleston, South Carolina
Conditions: Focal Segmental Glomerulosclerosis
Register for Updates
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT05028348
Recruiting
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2023
Locations: Medical University of South Carolina. Hollings Cancer Center, Charleston, South Carolina
Conditions: Multiple Myeloma
Register for Updates
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
NCT01838512
Recruiting
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2023
Locations: Charleston Oncology, Charleston, South Carolina +1 locations
Conditions: Multiple Myeloma
Register for Updates
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
NCT05267821
Recruiting
The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).
Gender:
All
Ages:
Between 1 day and 17 years
Trial Updated:
02/07/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Register for Updates
GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS
NCT05266001
Recruiting
The GRACE-2 study is a prospective, multi-center, double-blind, randomized controlled trial of the drug GM-CSF vs placebo in children with sepsis-induced multiple organ dysfunction syndrome (MODS) who have immunoparalysis with mild to moderate inflammation.
Gender:
All
Ages:
Between 1 day and 17 years
Trial Updated:
02/07/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome
Register for Updates
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC
NCT04295811
Recruiting
The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay (lab developed test) on cells collected using the EsoCheck (501k cleared device) to detect Barrett's Esophagus (BE), with or without dysplasia, and esophageal adenocarcinoma (EAC) as compared to Esophagogastroduodenoscopy (EGD) plus biopsies in both confirmed cases of BE/EAC and in controls (subjects without a prior diagnosis but undergoing screening for BE/EAC)
Gender:
Male
Ages:
50 years and above
Trial Updated:
01/23/2023
Locations: Lucid Investigative Site, Charleston, South Carolina
Conditions: Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
Register for Updates
Gravity Versus Vacuum Based Indwelling Tunneled Pleural Drainage System
NCT03831386
Recruiting
Malignant pleural effusion remains a debilitating complication of end stage cancer, which can be greatly improved by the introduction of the indwelling tunneled pleural catheter (IPC). However, there is no standard of care regarding drainage and limited data on the utility of different drainage techniques. In addition, many patients develop discomfort and chest pain during drainage. The investigators propose to evaluate gravity drainage and suction drainage on quality of life measures and outcom... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/06/2022
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Pleural Effusion
Register for Updates
TruGraf® Long-term Clinical Outcomes Study
NCT04491552
Recruiting
This is a prospective, multi-center, observational study. Subjects will have OmniGraf™ (TruGraf® and TRAC™) testing at study enrollment and thereafter every 3 months. In addition subjects will have OmniGraf™ (TruGraf® and TRAC™) testing at any time there is a clinical suspicion of acute rejection. Data collection for the primary objective extends over a 2-year period.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/10/2022
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Kidney Transplant Rejection
Register for Updates
An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)
NCT05070455
Recruiting
This is a Phase IV, multicenter, open-label study of Asceniv™ administered as an intravenous infusion of Asceniv™ (IGIV) 300-800 mg/kg every 21 or 28 days in approximately 12 pediatric subjects with Primary Immunodeficiency Diseases (PIDD). The study will be conducted at 5-7 centers in the United States, with subjects receiving six (28 day cycle) or seven (21 day cycle) doses of Asceniv™ during the study.
Gender:
All
Ages:
Between 2 years and 11 years
Trial Updated:
09/13/2022
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Primary Immune Deficiency
Register for Updates
Artisan Aphakia Lens for the Correction of Aphakia in Children
NCT01547442
Recruiting
The purpose of this study is to determine the safety and effectiveness of the Artisan Aphakia Lens in the treatment of aphakia in children.
Gender:
All
Ages:
Between 2 years and 21 years
Trial Updated:
06/24/2022
Locations: Medical University of South Carolina, Storm Eye Institute, Charleston, South Carolina
Conditions: Aphakia
Register for Updates
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
NCT03394365
Recruiting
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Gender:
All
Ages:
All
Trial Updated:
06/23/2022
Locations: Medical University of South Carolina (Adults and Pediatrics), Charleston, South Carolina
Conditions: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Register for Updates
Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)
NCT03540771
Recruiting
This is a comparative effectiveness study of two pragmatic models aiming to introduce palliative care for end stage liver disease patients. The 2 comparators are: Model 1: Consultative Palliative Care (i.e. direct access to Palliative Care provider), Model 2: Trained Hepatologist- led PC intervention (i.e. a hepatologist will receive formal training to deliver Palliative Care services) Primary Outcome: The change in quality of life from baseline to 3 months post enrollment as assessed by FACT-... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/05/2022
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: End Stage Liver Disease
Register for Updates